Published in Br J Cancer on June 01, 1982
Single bilayer liposomes prepared without sonication. Biochim Biophys Acta (1973) 3.83
Criteria for analyzing interactions between biologically active agents. Adv Cancer Res (1981) 2.49
Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles. Cancer Res (1976) 1.12
The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide. Clin Exp Immunol (1973) 1.01
Treatment of tumour bearing mice with liponsome-entrapped actinomycin D prolongs their survival. Res Commun Chem Pathol Pharmacol (1975) 0.95
Effects of entrapment in liposomes on the distribution, degradation and effectiveness of methotrexate in vivo. Ann N Y Acad Sci (1978) 0.89
Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo. Cancer Res (1980) 0.88
The effect of liposome (phospholipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours. Eur J Cancer (1981) 0.87
Liposome-encapsulated actinomycin D: potential in cancer chemotherapy. Proc Soc Exp Biol Med (1974) 0.87
Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210. Gan (1975) 0.82
Failure of actinomycin D entrapped in liposomes to prolong survival in renal cell adenocarcinoma-bearing mice. Oncology (1981) 0.81
A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52
Is azathioprine a better immunosuppressive than 6-mercaptopurine? Clin Exp Immunol (1971) 3.47
Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol (1977) 2.89
Postoperative depression of the lymphocyte response to phytohaemagglutinin. Lancet (1967) 2.57
Criteria for analyzing interactions between biologically active agents. Adv Cancer Res (1981) 2.49
Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity (1997) 2.17
The expected effect of a combination of agents: the general solution. J Theor Biol (1985) 2.06
In vivo biological activity of the components of haematoporphyrin derivative. Br J Cancer (1982) 1.82
Photodynamic destruction of human bladder carcinoma. Br J Cancer (1975) 1.55
Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. Br J Cancer (1986) 1.53
Time-dependent immunosuppressive effects of anti-thymocyte serum. Nature (1967) 1.48
meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. Br J Cancer (1986) 1.47
Dose-response curves for agents that impair cell reproductive integrity. A fundamental difference between dose-response curves of antimetabolites and those for radiation and alkylating agents. Br J Cancer (1969) 1.44
Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer (1991) 1.42
Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. EMBO J (1996) 1.40
Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res (1974) 1.36
p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Mol Cell Biol (1999) 1.30
Depression of lymphocyte responses after surgical trauma. Br J Exp Pathol (1973) 1.29
Correlations between methods for measurement of synergy. J Infect Dis (1980) 1.29
The growth of human tumours in immunosuppressed mice and their response to chemotherapy. Br J Cancer (1974) 1.27
In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents. Cancer Chemother Rep (1972) 1.26
Cell respiration as a requirement for antibody release in vitro. Nature (1968) 1.21
Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. Biochem J (1989) 1.19
A raft technique for chemotaxis: a versatile method suitable for clinical studies. J Immunol Methods (1976) 1.15
Synergistic effect of cortisol and prostaglandin E2 on the PHA response. Relation to immunosuppression induced by trauma. Clin Exp Immunol (1976) 1.11
The therapeutic significance of the dose response curve for antilymphocytic serum. Transplantation (1971) 1.02
The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide. Clin Exp Immunol (1973) 1.01
Immunosuppression by L-asparaginase. Nature (1970) 0.99
The relation between the physico-chemical properties and immunosuppressive effects of an homologous series of sulphonic acid esters. Immunology (1967) 0.97
The sensitivity to chemotherapeutic agents of a rat tumour grown in immunosuppressed mice. Br J Cancer (1971) 0.95
Synergy with double and triple antibiotic combinations compared. J Antimicrob Chemother (1983) 0.95
Effects of L-asparaginase on lymphocyte-target cell reactions in vitro. Nature (1970) 0.95
Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative. Br J Cancer (1985) 0.94
Immunosuppressive agents: the design of selective therapeutic schedules. Antibiot Chemother (1969) 0.93
The rabbit VX2 tumour as a model for carcinomas of the tongue and larynx. Acta Otolaryngol (1989) 0.91
Defective in vitro antibody production in response to pokeweed mitogen and influenza antigen in patients with Hodgkin's disease. Clin Exp Immunol (1985) 0.90
Synergy assessment with growth curves. J Infect Dis (1984) 0.90
Radiosensitivity of immunologically activated cells. Nature (1966) 0.89
Minor synergy and antagonism may be clinically important. J Antimicrob Chemother (1987) 0.88
Selective suppression of murine antibody-dependent cell-mediated cytotoxicity by azathioprine. Transplantation (1975) 0.87
HPD - a study of its components and their properties. Adv Exp Med Biol (1983) 0.87
The localization of haemolytic antibody in sections of lymphoid organs: an improved method. Immunology (1970) 0.84
Synergy and antagonism are not synonymous with therapeutic advantage and disadvantage. J Antimicrob Chemother (1988) 0.84
Role of mitosis and mitotic inhibition in the immunosuppressive action of thioguanine. Nature (1966) 0.83
Consequences of synergy between environmental carcinogens. Environ Res (1985) 0.82
Protective effects of a novel perfluorochemical emulsion in photodynamic therapy. Biomater Artif Cells Immobilization Biotechnol (1992) 0.82
The effect of cysteine on the immunosuppressive activity of busulphan, cyclophosphamide and nitrogen mustard. Br J Cancer (1971) 0.82
Time-dependence and selectivity of immunosuppressive agents. Immunology (1979) 0.82
Effect of cyclophosphamide on the homograft response in the guinea pig. Transplantation (1965) 0.81
Transplantation and immunosuppression. Mod Trends Immunol (1967) 0.81
Effect of some metabolic inhibitors on plaque formation in Jerne plates. Nature (1967) 0.81
The mode of action of cytotoxic drugs. Proc R Soc Med (1970) 0.80
Differential asparaginase sensitivity of T-cell and B-cell responses. Clin Exp Immunol (1973) 0.80
Porphyrin sensitizers in tumour phototherapy. Novel sensitizers of the chlorin and bacteriochlorin class with amphiphilic properties. J Photochem Photobiol B (1990) 0.79
Letter: Predicting response of human cancer to chemotherapy. Lancet (1974) 0.78
Immunosuppressive agents: generation and consequences of differing dose-response curves. Proc R Soc Med (1972) 0.78
Research ethics and deception. Lancet (1980) 0.78
Intercellular immunological controls and modulation of cyclic AMP levels. Some doubts. Immunology (1976) 0.77
Immunosuppression by platinum diamines. Br J Cancer (1971) 0.77
Photodynamic therapy of a mouse glioma: intracranial tumours are resistant while subcutaneous tumours are sensitive. Br J Cancer (1991) 0.77
Neutrophil function during chemotherapy for Hodgkin's disease. Br J Cancer (1981) 0.77
Modes of action of immunosuppressive agents. Proc R Soc Med (1967) 0.75
Concepts for describing the interaction of two agents. Radiat Res (1991) 0.75
Thymus-dependent and thymus-independent antibody responses: contrasting patterns of immunosuppression. Br J Exp Pathol (1981) 0.75
Autoimmunity and immunosuppression. Proc R Soc Med (1967) 0.75
Dose-response curves for agents that impair cell reproductive integrity. The relation between dose-response curves and the design of selective regimens in cancer chemotherapy. Br J Cancer (1969) 0.75
The immunosuppressive effects of 5-fluorocytosine and 5-fluorouracil. Chemotherapy (1979) 0.75
The last surviving cancer cell: the chances of killing it. Cancer Chemother Rep (1968) 0.75
Antagonism between radiosensitizing agents. Br J Radiol (1988) 0.75
Intrathecal interferon, indomethacin, and multiple sclerosis. Lancet (1987) 0.75
Subcutaneous Corynebacterium parvum in bladder cancer: a controlled study of its immunological effects. Br J Urol (1979) 0.75
Anti-HIV synergy between dextran sulphate and zidovudine. Lancet (1987) 0.75
Effect of L-asparaginase on germinal centre haemolysin. Nature (1971) 0.75
Antibody response by cells cultured on dialysis membrane in disposable plastic vessels. J Immunol Methods (1975) 0.75
Growth of human and rat tumours in immunosuppressed mice. J Pathol (1972) 0.75
Muscle damage and recovery in the rabbit tongue following photodynamic therapy with haematoporphyrin derivative. Acta Otolaryngol (1991) 0.75